Know Cancer

or
forgot password

Efficacy and Tolerability of Intravenous Zoledronic Acid 4mg as an Adjunct to Standard Therapies Including Conversion From Pamidronate in Breast Cancer Patients With Metastatic Bone Lesions. A Prospective, Randomised, Open-label, Clinical Study


Phase 3
18 Years
N/A
Not Enrolling
Female
Breast Cancer With Bone Metastasis

Thank you

Trial Information

Efficacy and Tolerability of Intravenous Zoledronic Acid 4mg as an Adjunct to Standard Therapies Including Conversion From Pamidronate in Breast Cancer Patients With Metastatic Bone Lesions. A Prospective, Randomised, Open-label, Clinical Study

Inclusion Criteria


Inclusion criteria

- Confirmed diagnosis of Breast Cancer with at least one breast cancer-related bone
lesion

- No treatment with bisphosphonates within 6 months prior to inclusion into the study

- Good health status (ECOG Performance status 0-2)

Exclusion criteria

- Patients who do not have at least one breast cancer-related bone lesion that is
detectable on conventional radiographs of bone (plain film) at screening

- Abnormal renal function

- History of diseases with influence on bone metabolism such as Paget's disease and
primary hyperparathyroidism

- Pregnancy and lactation

- Current active dental problems including infection of the teeth or jawbone (maxilla
or mandibular); dental or fixture trauma, or a current or prior diagnosis of
osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing
after dental procedures, recent (within 6 weeks) or planned dental or jaw surgery
(e.g..extraction, implants)

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy of a switch over from pamidronate therapy (2 infusions) to a treatment with zoledronic acid 4mg every 4 weeks (10 infusions) for 44 weeks in patients with breast cancer-related bone lesions

Principal Investigator

Novartis

Investigator Role:

Study Chair

Investigator Affiliation:

Novartis

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

CZOL446EDE03

NCT ID:

NCT00372710

Start Date:

August 2002

Completion Date:

Related Keywords:

  • Breast Cancer With Bone Metastasis
  • Breast cancer
  • Palliation
  • Bone metastasis
  • Zoledronic acid
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Bone Neoplasms
  • Bone Marrow Diseases

Name

Location